舒肝解郁胶囊治疗轻中度类风湿关节炎伴轻中度抑郁症的临床疗效研究

目的 观察舒肝解郁胶囊治疗轻中度类风湿关节炎(rheumatoid arthritis,RA)伴轻中度抑郁症的有效性以及安全性.方法 本研究采用病例对照的方法,选取2017年5月—2018年12月期间重庆三峡中心医院血液风湿科门诊及住院的轻中度RA伴轻中度抑郁症患者120例,随机分为空白组、治疗组、对照组,每组各40例...

Clinical Efficacy of Shugan Jieyu Capsules in Treating Mild to Moderate Rheumatoid Arthritis with Depression

Objective To observe the efficacy and safety of Shugan Jieyu capsules in treating mild to moderate rheumatoid arthritis(RA)with mild to moderate depression.Methods A case-control study was conducted.From May2017 to December 2018,120 patients with mild to moderate RA in the Department of Hematology and Rheumatology of Chongqing Three Gorges Central Hospital were selected and randomly divided into blank group and treatment group.,Control group,40 cases in each group.The three groups of patients were given basic treatment with non-steroidal anti-inflammatory drugs(NSAIDs)and slow-acting anti-RA drugs(disease modifying antirheumatic drugs,DMARDs),and the treatment group was given Shugan Jieyu capsule treatment,control One group was given paroxetine treatment,and the three groups were given continuous treatment for 24 weeks.The three groups of patients were treated with disease activity score-28(DAS28)and Hamilton’s depression scale(HAMD)before treatment and 2,8,12,and 24 weeks after treatment.Score,self-rating depression scale(SDS)score,and compare its clinical efficacy and adverse reactions through scores.Results The DAS28 scores of the three groups of patients after 8,12,and 24 weeks of treatment were significantly lower than those before the treatment(P<0.05);and the DAS28 scores of the treatment group and the control group after 8,12,and 24 weeks of treatment were lower than the blank group at the same time node(P<0.05),but there was no significant difference in DAS28 score between the control group and the treatment group(P>0.05).The HAMD scale scores of the patients in the control group and the treatment group after 2,8,12,and 24 weeks of treatment were significantly lower than those before the treatment(P<0.05);and the patients in the control group and the treatment group were HAMD after 2,8,12,and 24 weeks of treatment The scale scores were significantly lower than those of the blank group at the same time(P<0.05),but there was no significant difference between the control group and the treatment group in the HAMD scale scores(P>0.05).The SDS scale scores of patients in the control group and the treatment group after 2,8,12,and 24 weeks of treatment were significantly lower than those before the treatment(P<0.05);and the patients in the control group and the treatment group had SDS after 2,8,12,and 24 weeks of treatment The scale scores were significantly lower than those of the blank group at the same time(P<0.05),but there was no statistically significant difference in the SDS scale scores between the control group and the treatment group(P>0.05).There were no obvious adverse reactions in the control group and the treatment group.Conclusion Shugan Jieyu Capsule has the same curative effect as paroxetine in treating patients with mild to moderate RA with mild to moderate depression.It can synergize the curative effect of anti-RA drugs,improve the overall clinical curative effect of treatment of RA,and reduce disease activity.